Neuromuscular Disorders

Papers
(The H4-Index of Neuromuscular Disorders is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to go90
The 2021 version of the gene table of neuromuscular disorders (nuclear genome)45
Fatigue in patients with myasthenia gravis. A systematic review of the literature39
Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy39
Combining genetics, neuropsychology and neuroimaging to improve understanding of brain involvement in Duchenne muscular dystrophy - a narrative review38
The 2022 version of the gene table of neuromuscular disorders (nuclear genome)36
Recent advances in nemaline myopathy36
Guillain-Barré-Strohl syndrome and COVID-19: Case report and literature review31
X-linked myotubular myopathy31
Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen28
Congenital muscular dystrophies: What is new?26
Chronic pain is common in mitochondrial disease25
Age and baseline values predict 12 and 24-month functional changes in type 2 SMA24
Strength-training effectively alleviates skeletal muscle impairments in myotonic dystrophy type 123
The DMD gene and therapeutic approaches to restore dystrophin23
Understanding European patient expectations towards current therapeutic development in spinal muscular atrophy23
Clinical practice guidelines for glycogen storage disease V & VII (McArdle disease and Tarui disease) from an international study group21
Gain and loss of abilities in type II SMA: A 12-month natural history study21
Cognitive impairment appears progressive in the mdx mouse20
Disease-modifying effects of edasalonexent, an NF-κB inhibitor, in young boys with Duchenne muscular dystrophy: Results of the MoveDMD phase 2 and open label extension trial19
0.034800052642822